Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05701306 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jun 1, 2026 → Jun 1, 2027
See other at-risk trials from Ascentage Pharma Group Inc.

Record History

  1. Primary completion pushed from Jun 1, 2026 to Jun 1, 2027 Phase changed: Phase 1 → Phase 1/2 · Eligibility criteria expanded, about 12 words · Study title shortened, about 2 wordsv6 Show 3 more changesShow less
    • Phase changed: Phase 1 → Phase 1/2
    • Eligibility criteria expanded, about 12 words
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv5
  3. Study sites: 1 to 3v4
  4. Start date: Mar 23, 2023 to Feb 28, 2023v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Feb 1, 2023 to Mar 23, 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Feb 1, 2023 to Mar 23, 2023
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open, non-randomized Phase Ib-II trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory neuroblastoma or solid tumors.
Trial Details
NCT Number NCT05701306
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Suzhou Yasheng Pharmaceutical Co., Ltd.
Conditions Neuroblastoma, Solid Tumor
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov